Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of XP-004 Personlaized mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer

NCT06496373 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT06496373
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06496373 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of XP-004 Personlaized mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer
Lead sponsor
Ruijin Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
July 16, 2024
Completion date
June 30, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-intolerant, pancreatic cancer resectable